Drug Report History #2544
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v6-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated (Changed) | Updated to: 2017-10-03 | Was: 2017-03-14 |
| Drug Identification Number | 02254603 | 02254603 |
| Brand name | PEGETRON | PEGETRON |
| Common or Proper name | peginterferon alfa-2b Powder for Solution / ribavirin Capsules | peginterferon alfa-2b Powder for Solution / ribavirin Capsules |
| Company Name | MERCK CANADA INC | MERCK CANADA INC |
| Ingredients | PEGINTERFERON ALFA-2B RIBAVIRIN | PEGINTERFERON ALFA-2B RIBAVIRIN |
| Strength(s) | 100MCG 200MG | 100MCG 200MG |
| Dosage form(s) | CAPSULE POWDER FOR SOLUTION | CAPSULE POWDER FOR SOLUTION |
| Route of administration | ORAL SUBCUTANEOUS | ORAL SUBCUTANEOUS |
| Packaging size (Changed) | Updated to: 56 Capsules / 2 CLEARCLICK Pens (dispositifs) | Was: 56 Capsules / 2 CLEARCLICK Pens |
| Additional packaging sizes | ||
| ATC code | L03AB | L03AB |
| ATC description | IMMUNOSTIMULANTS | IMMUNOSTIMULANTS |
| Reason for discontinuation | Business reasons | Business reasons |
| Anticipated discontinuation date (Changed) | Updated to: 2017-09-30 | Was: 2017-06-30 |
| Actual discontinuation date (Changed) | Updated to: 2017-10-02 | Was: |
| Remaining supply date (Changed) | Updated to: 2017-06-02 | Was: 2017-06-30 |
| Discontinuation status (Changed) | Updated to: Discontinued | Was: To be discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | ||
| Health Canada comments |